News of Note - February 22, 2023
BULL BEAR BRES|NAHAN
Wednesday, February 22, 2023
Riders on the storm
Riders on the storm
Into this house, we're born
Into this world, we're thrown
Like a dog without a bone
An actor out on loan
Riders on the storm
Like a hitchhiker, into your vehicle, you ought to be mindful of what you let into your portfolio and investment strategy.. Don’t just pick things up along the highway unless you’re ready to deal with ‘a rider on the storm’.
Elranatamab Receives FDA and EMA Filing Acceptance
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
FDA has granted Priority Review
FDA’s decision on the application is expected in 2023
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Islatravir and other HIV data presented at CROI 2023
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.
Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases.
AZN LN | AZN SS | AZN
Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers
Approvals based on significant survival benefits in HIMALAYA and POSEIDON Phase III trials
Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia
Tablet formulation can be co-administered with gastric acid-reducing agents
allowing greater patient and physician choice
Approval based on ELEVATE-PLUS trials which showed
bioequivalence and consistent dosing vs. current capsule
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.
STLAM IM | STLAP FP | STLA
Stellantis N.V. engages in the design, engineering, manufacturing, distribution, and sale of automobiles and light commercial vehicles, engines, transmission systems, metallurgical products, and production systems worldwide.
Remain on the sidelines due to the Norwegian governments tax shenanigans..
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, the United States, Canada, Norway, rest of Europe, and internationally.
UCB BB | UCBJY
Sales are important, yes, though the real story here is ‘Bimekizumab’ and the pipeline..
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. -CapIQ
Announces Change to its Board of Directors
Founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally.
McKinsey Plans to Eliminate About 2,000 Jobs in One of Its Biggest Rounds of Cuts
Firm that advises on headcount reductions takes aim at its own
One of management consultant’s biggest rounds of job cuts ever
Dutch Premier Pokes China While Praising ‘Century of America’
“The 21st century will be the century of democracy and thus the century of America.”
Morgan Stanley: Welcome to the ‘death zone’
Does a double-black-diamond run await?
Bottom line, investors are not bearish any longer, and this is just another reason to be wary of the set-up going into what is likely to be another weak earnings season.
Dutch group sues AbbVie for human rights violations stemming from Humira pricing
The latest lawsuit, however, goes beyond the usual discussion of excessive pricing and abusing a dominant market position by arguing that AbbVie had a “social duty of care” to ensure that its practices did not impede access to legally insured basic care.
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
SCOTUS “confused” after hearing arguments for weakening Section 230 immunity
SCOTUS sways Google’s way, says eroding Section 230 could crash digital economy